A Double-Blind, Placebo-Controlled Study of Caripazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder.

Trial Profile

A Double-Blind, Placebo-Controlled Study of Caripazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2012

At a glance

  • Drugs Cariprazine; Citalopram; Duloxetine; Escitalopram; Sertraline; Venlafaxine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2012 Actual patient number changed from 204 to 232 according to ClinicalTrials.gov.
    • 06 Apr 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 06 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top